India, Feb. 10 -- Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a product for the treatment of acne vulgaris in the United Kingdom.
In a joint statement, the companies said they have received approval for Winlevi, a topical treatment for acne vulgaris in patients aged 12 years and older.
As part of the agreement inked in September 2023, Glenmark in-licensed the product from Cosmo Pharmaceuticals for distribution in Europe and South Africa.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....